> Shares in Hansa Medical (STO:HMED) climbed 86% in three days following the release of an analyst report. The report predicted a rosy future for Hansa and its lead candidate IdeS, resulting in investors driving the stock partway to the SEK 250 ($28) target set by the analysts. Article (Swedish)
> Molecular Partners (SWX:MOLN) CEO Christian Zahnd resigned due to health reasons. Zahnd, who co-founded the company, will be replaced on an interim basis by COO Patrick Amstutz. The COO stepped up on an interim basis for five months last year to cover temporary medical leave. Molecular Partners is now looking internally and externally for a full-time CEO. Release
> A Phase III trial of binimetinib in combination with encorafenib in BRAF-mutant melanoma met its primary endpoint. The combination of the MEK and BRAF inhibitors, the rights to which are part-owned by Pierre Fabre, bested Roche’s ($RHHBY) Zelboraf in terms of progression-free survival. Release
> Enterprise Therapeutics raised £4 million ($5 million). The Brighton, U.K.-based respiratory disease startup will use the money to move its three discovery programs toward candidate selection. Cystic fibrosis and COPD are among the indications being looked at by the team. Release
> Cell Medica expanded its collaboration with Baylor College of Medicine. The partners are looking to create off-the-shelf CAR-modified natural killer T cells. Cell Medica has an exclusive option to pick up products and technologies resulting from the collaboration. Release
> Genmab (CPH:GEN) unveiled another Phase III trial of Darzalex. Johnson & Johnson ($JNJ), which is developing the drug with Genmab, facilitated the trial by inking a pact with Amgen ($AMGN). The deal positions J&J to run a trial combining Darzalex with Kyprolis, the multiple myeloma drug Amgen acquired in its takeover of Onyx Pharmaceuticals. Release